{ "schema_version": 1, "kind": "condition", "id": "sarcoidosis-referral", "name": "Pulmonary Sarcoidosis (Referral & Initial Management)", "category": "chronic", "sources": "BTS Clinical Statement on Pulmonary Sarcoidosis 2020 for the regimen, with the dose from Egyptian National Drug Formulary - Endocrine System Drugs 2024, Prednisolone monograph (printed pages 169-170): \"Oral: Usual Initial doses: 5 to 60 mg/day given in a single daily dose or in 2 to 4 divided doses.\" and, for children, \"Infants, Children, and Adolescents: Oral: initial: 0.1 to 2 mg/kg/day (4 to 60 mg/m2 BSA/day), in divided doses 1 to 4 times daily.\" The formulary states general ranges rather than a sarcoidosis regimen; the starting dose and the taper are from the BTS statement, which is not held in this corpus. · BTS Clinical Statement on Pulmonary Sarcoidosis 2020", "review_status": "reviewed", "verified_against": "BTS Clinical Statement on Pulmonary Sarcoidosis 2020 for the regimen, with the dose from Egyptian National Drug Formulary - Endocrine System Drugs 2024, Prednisolone monograph (printed pages 169-170): \"Oral: Usual Initial doses: 5 to 60 mg/day given in a single daily dose or in 2 to 4 divided doses.\" and, for children, \"Infants, Children, and Adolescents: Oral: initial: 0.1 to 2 mg/kg/day (4 to 60 mg/m2 BSA/day), in divided doses 1 to 4 times daily.\" The formulary states general ranges rather than a sarcoidosis regimen; the starting dose and the taper are from the BTS statement, which is not held in this corpus. · BTS Clinical Statement on Pulmonary Sarcoidosis 2020 · Sarcoidosis - disease-level clinical article (sarcoidosis-referral-clinical.txt)", "verified_date": "2026-08", "treatments": [ { "id": 1574, "generic": "Prednisolone", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": 5.0, "adult_dose": "20-40 mg once daily in the morning under specialist pulmonology supervision", "adult_duration": "4-6 weeks initial, then gradual taper", "dose_source": "BTS Clinical Statement on Pulmonary Sarcoidosis 2020 for the regimen, with the dose from Egyptian National Drug Formulary - Endocrine System Drugs 2024, Prednisolone monograph (printed pages 169-170): \"Oral: Usual Initial doses: 5 to 60 mg/day given in a single daily dose or in 2 to 4 divided doses.\" and, for children, \"Infants, Children, and Adolescents: Oral: initial: 0.1 to 2 mg/kg/day (4 to 60 mg/m2 BSA/day), in divided doses 1 to 4 times daily.\" The formulary states general ranges rather than a sarcoidosis regimen; the starting dose and the taper are from the BTS statement, which is not held in this corpus.", "rationale": "Prednisolone is a corticosteroid that suppresses the granulomatous inflammation of pulmonary sarcoidosis; it is reserved for symptomatic or progressive disease under specialist supervision, since asymptomatic early-stage disease often does not need systemic treatment.", "cautions": [ "Requires specialist diagnostic verification (tissue biopsy, HRCT scan, serum ACE level).", "Monitor for corticosteroid adverse effects (hyperglycemia, osteoporosis, hypertension, cataracts).", "Asymptomatic Stage I sarcoidosis often does not require systemic steroid treatment." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Specialist pediatric pulmonology/rheumatology referral", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "HOSTACORTIN H 5MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 12.0, "pack_count": 30, "unit_price": 0.4, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PREDNISOLONE 5 MG 20 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ARAB DRUG COMPANY (ADCO)", "price_egp": 24.0, "pack_count": 20, "unit_price": 1.2, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PREDILONE 5MG 10 TAB. (25 STRIPS PACK)", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "KAHIRA", "price_egp": 250.0, "pack_count": 10, "unit_price": 25.0, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "EPICOPRED 5 MG 30 ORODISPERSIBLE TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EIPICO", "price_egp": 69.0, "pack_count": null, "unit_price": null, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PREDNISOLONE-EVA 5 MG 30 ORODISPERSIBLE TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EVA PHARMA", "price_egp": 79.5, "pack_count": null, "unit_price": null, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DISPRELONE-OD 5 MG 30 ORODISPERSABLE TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ANDALOUS PHARMA", "price_egp": 84.0, "pack_count": null, "unit_price": null, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "SOLUPRED ORO 5 MG 30 ORODISPERSIBLE TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI WINTHROP > SANOFI", "price_egp": 84.0, "pack_count": null, "unit_price": null, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ACETASEE 1% EYE DROPS (SUSP.) 5 ML", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA", "price_egp": 7.5, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null }, { "trade_name": "PREDNIS 5MG/5ML SYRUP 100 ML", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PHAROPHARMA", "price_egp": 9.5, "pack_count": null, "unit_price": null, "strength_mg": 5.0, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null } ], "condition_id": "sarcoidosis-referral" }, { "id": 1575, "generic": "Referral & safety-netting (no drug therapy)", "line": 1, "is_adjunct": false, "form": null, "strength_mg": null, "adult_dose": null, "adult_duration": null, "dose_source": "Sarcoidosis - disease-level clinical article (sarcoidosis-referral-clinical.txt)", "rationale": "Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.", "cautions": [ "RED FLAG - A prophylactic implantable cardioverter-defibrillator is recommended for patients with cardiac sarcoidosis.", "RED FLAG - The symptoms suggestive of organ involvement that should be reported promptly are worsening dyspnea, chest pain, palpitations, syncope, visual disturbances, neurologic symptoms, or persistent fatigue.", "RED FLAG - Ocular involvement (uveitis, present in ~50% of patients) requires referral to an ophthalmologist and regular eye examinations." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": null, "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [], "condition_id": "sarcoidosis-referral" } ] }